[1]

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians 75:10−45

doi: 10.3322/caac.21871
[2]

Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, et al. 2023. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation 147:e93−e621

doi: 10.1161/CIR.0000000000001123
[3]

GBD 2019 Stroke Collaborators. 2021. Global, regional, and national burden of stroke and its risk factors, 1990−2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology 20:795−820

doi: 10.1016/S1474-4422(21)00252-0
[4]

Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, et al. 2023. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduction and Targeted Therapy 8:98

doi: 10.1038/s41392-023-01333-7
[5]

Ringel MS, Scannell JW, Baedeker M, Schulze U. 2020. Breaking Eroom's Law. Nature Reviews Drug Discovery 19:833−34

doi: 10.1038/d41573-020-00059-3
[6]

Dall'Agnese A, Zheng MM, Moreno S, Platt JM, Hoang AT, et al. 2025. Proteolethargy is a pathogenic mechanism in chronic disease. Cell 188:207−221.e30

doi: 10.1016/j.cell.2024.10.051
[7]

Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, et al. 2017. A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery 16:19−34

doi: 10.1038/nrd.2016.230
[8]

Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, et al. 2022. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 55:1749

doi: 10.1016/j.immuni.2022.07.021
[9]

Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, et al. 2007. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. American Heart Journal 153:335.e1−335.e8

doi: 10.1016/j.ahj.2006.10.031
[10]

Chen C, Wang Z, Qin Y. 2022. Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. Frontiers in Pharmacology 13:935536

doi: 10.3389/fphar.2022.935536
[11]

Kanwore K, Kanwore K, Adzika GK, Abiola AA, Guo X, et al. 2022. Cancer metabolism: the role of immune cells epigenetic alteration in tumorigenesis, progression, and metastasis of glioma. Frontiers in Immunology 13:831636

doi: 10.3389/fimmu.2022.831636
[12]

Chander S, Bhatt S, Dua K, Jadhav H. 2023. Editorial: recent trends and spotlight on nucleotide-based drugs: novel targets, their design, delivery, and clinical potential. Frontiers in Pharmacology 14:1245809

doi: 10.3389/fphar.2023.1245809
[13]

Ryszkiewicz P, Malinowska B, Schlicker E. 2023. Polypharmacology: promises and new drugs in 2022. Pharmacological Reports 75:755−70

doi: 10.1007/s43440-023-00501-4
[14]

Werida R, Khairat I, Khedr NF. 2021. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomedecine & Pharmacotherapie 135:111179

doi: 10.1016/j.biopha.2020.111179
[15]

McClure EW, Daniels RN. 2021. Classics in chemical neuroscience: amitriptyline. ACS Chemical Neuroscience 12:354−62

doi: 10.1021/acschemneuro.0c00467
[16]

Hansford R, Buller S, Tsang AH, Benoit S, Roberts AG, et al. 2025. Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism. Cell Metabolism 37:1820−1834.e5

doi: 10.1016/j.cmet.2025.07.009
[17]

Hu Q, Zhang YW, Zhang YN, Zhu GH, Chen PC, et al. 2025. Uncovering the naturally occurring covalent inhibitors of SARS-CoV-2 Mpro from the Chinese medicine sappanwood and deciphering their synergistic anti-Mpro effects. Journal of Ethnopharmacology 342:119397

doi: 10.1016/j.jep.2025.119397
[18]

Zhu GH, Zhang YN, Xiong Y, Hou XD, Zhang QG, et al. 2025. Uncovering the covalent inhibitors of SARS-CoV-2 Mpro in Tibetan edible herb Rhodiola crenulata and their synergistic anti-Mpro mechanism. Journal of Pharmaceutical Analysis 101224

doi: 10.1016/j.jpha.2025.101224
[19]

Zhu G, Zhang Y, Qi S, Xu J, Xiong Y, et al. 2025. Highly efficient discovery of the covalent Mpro inhibitors from crude Pu-erh tea by integrating biochemical and chemoproteomic approaches. Food Science and Human Wellness 14:9250120

doi: 10.26599/fshw.2024.9250120
[20]

Raji L, Tetteh A, Ruhul Amin ARM. 2023. Role of c-Src in carcinogenesis and drug resistance. Cancers 16:32

doi: 10.3390/cancers16010032
[21]

Liu Y, Li C, Liu H, Tan S. 2024. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress. Archives of Pharmacal Research 47:442−64

doi: 10.1007/s12272-024-01494-1
[22]

Okur Z, Schlauri N, Bitsikas V, Panopoulou M, Ortiz R, et al. 2024. Control of neuronal excitation–inhibition balance by BMP–SMAD1 signalling. Nature 629:402−9

doi: 10.1038/s41586-024-07317-z
[23]

Hayat R, Manzoor M, Hussain A. 2022. Wnt signaling pathway: a comprehensive review. Cell Biology International 46:863−77

doi: 10.1002/cbin.11797
[24]

Ganguly A, Dey M, Scott C, Duong VK, Arun Dahanukar A. 2021. Dietary macronutrient imbalances lead to compensatory changes in peripheral taste via independent signaling pathways. The Journal of Neuroscience 41:10222−46

doi: 10.1523/JNEUROSCI.2154-20.2021
[25]

Bolus MF, Willats AA, Rozell CJ, Stanley GB. 2021. State-space optimal feedback control of optogenetically driven neural activity. Journal of Neural Engineering 18:036006

doi: 10.1088/1741-2552/abb89c
[26]

Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, et al. 2024. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity. Cell 187:4355−4372.e22

doi: 10.1016/j.cell.2024.07.016
[27]

Singh RS. 2023. A law of redundancy compounds the problem of cancer and precision medicine. Journal of Molecular Evolution 91:711−20

doi: 10.1007/s00239-023-10131-2
[28]

Gates AJ, Brattig Correia R, Wang X, Rocha LM. 2021. The effective graph reveals redundancy, canalization, and control pathways in biochemical regulation and signaling. Proceedings of the National Academy of Sciences of the United States of America 118:e2022598118

doi: 10.1073/pnas.2022598118
[29]

Yang M, Xiang H, Luo G. 2024. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders. Biochemical Pharmacology 224:116246

doi: 10.1016/j.bcp.2024.116246
[30]

Jin Q, Huang F, Xu X, He H, Zhang Y. 2021. High expression of hypoxia inducible factor 1α related with acquired resistant to EGFR tyrosine kinase inhibitors in NSCLC. Scientific Reports 11:1199

doi: 10.1038/s41598-020-79801-1
[31]

Jokela TA, LaBarge MA. 2021. Integration of mechanical and ECM microenvironment signals in the determination of cancer stem cell states. Current Stem Cell Reports 7:39−47

doi: 10.1007/s40778-020-00182-2
[32]

Faisal SM, Comba A, Varela ML, Argento AE, Brumley E, et al. 2022. The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. Frontiers in Oncology 12:1005069

doi: 10.3389/fonc.2022.1005069
[33]

Holzmann K, Sutterlüty H. 2023. Signal transduction as an assimilation of signals with different origins and different intracellular states. International Journal of Molecular Sciences 24:10085

doi: 10.3390/ijms241210085
[34]

Xie C, Lin Y, Qi C, Wang W, Yuan Y, et al. 2025. Neuro-endocrine-immune regulation of metabolic homeostasis. Cytokine & Growth Factor Reviews 85:165−78

doi: 10.1016/j.cytogfr.2025.08.001
[35]

Kim J, Hopper C, Cho KH. 2023. Statistical control of structural networks with limited interventions to minimize cellular phenotypic diversity represented by point attractors. Scientific Reports 13:6275

doi: 10.1038/s41598-023-33346-1
[36]

Liu MJ, Yeh FJ, Yvon R, Simpson K, Jordan S, et al. 2024. Extracellular pectin-RALF phase separation mediates FERONIA global signaling function. Cell 187:312−330.e22

doi: 10.1016/j.cell.2023.11.038
[37]

Kleist AB, Szpakowska M, Talbot LJ, Slodkowicz G, Malinverni D, et al. 2025. Encoding and decoding selectivity and promiscuity in the human chemokine-GPCR interaction network. Cell 188:3603−3622.e27

doi: 10.1016/j.cell.2025.03.046
[38]

Curran CS, Kopp JB. 2022. Aryl hydrocarbon receptor mechanisms affecting chronic kidney disease. Frontiers in Pharmacology 13:782199

doi: 10.3389/fphar.2022.782199
[39]

Xu L, Lin L, Xie N, Chen W, Nong W, et al. 2024. Role of aryl hydrocarbon receptors in infection and inflammation. Frontiers in Immunology 15:1367734

doi: 10.3389/fimmu.2024.1367734
[40]

Guan XJ, Zhang YY, Zheng X, Hao HP. 2021. Drug discovery inspired from nuclear receptor sensing of microbial signals. Trends in Molecular Medicine 27:624−26

doi: 10.1016/j.molmed.2021.03.007
[41]

Cheng L, Wu H, Chen Z, Hao H, Zheng X. 2023. Gut microbiome at the crossroad of genetic variants and behavior disorders. Gut Microbes 15:2201156

doi: 10.1080/19490976.2023.2201156
[42]

Zheng X, Cai X, Hao H. 2022. Emerging targetome and signalome landscape of gut microbial metabolites. Cell Metabolism 34:35−58

doi: 10.1016/j.cmet.2021.12.011
[43]

Fuchs CD, Trauner M. 2022. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nature Reviews Gastroenterology & Hepatology 19:432−50

doi: 10.1038/s41575-021-00566-7
[44]

Turocy T, Crawford JM. 2025. Bacterial small molecule metabolites implicated in gastrointestinal cancer development. Nature Reviews Microbiology 23:106−21

doi: 10.1038/s41579-024-01103-4
[45]

Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, et al. 2023. Gut−liver axis: barriers and functional circuits. Nature Reviews Gastroenterology & Hepatology 20:447−61

doi: 10.1038/s41575-023-00771-6
[46]

Cani PD, Van Hul M. 2024. Gut microbiota in overweight and obesity: crosstalk with adipose tissue. Nature Reviews Gastroenterology & Hepatology 21:164−83

doi: 10.1038/s41575-023-00867-z
[47]

Chen Z, Zhou J, Zheng X, Xie H, Hao H. 2025. Metabolic insights into gut microbiota in the pharmacology of natural medicines. Chinese Journal of Natural Medicines 23:158−68

doi: 10.1016/S1875-5364(25)60820-X
[48]

Zhou J, Fan Q, Cai X, Zhang Y, Hou Y, et al. 2023. Ginkgo biloba extract protects against depression-like behavior in mice through regulating gut microbial bile acid metabolism. Chinese Journal of Natural Medicines 21:745−58

doi: 10.1016/S1875-5364(23)60496-0
[49]

Wang W, Liu Y, Xu Q, Liu L, Zhu M, et al. 2025. Cellular crosstalk in organotypic vasculature: mechanisms of diabetic cardiorenal complications and SGLT2i responses. Cardiovascular Diabetology 24:90

doi: 10.1186/s12933-025-02655-2
[50]

Liu T, Wu H, Wei J. 2025. Beyond the brain: exploring the multi-organ axes in Parkinson's disease pathogenesis. Journal of Advanced Research

doi: 10.1016/j.jare.2025.05.034
[51]

Romero A, Eckel J. 2021. Organ crosstalk and the modulation of insulin signaling. Cells 10:2082

doi: 10.3390/cells10082082
[52]

Zhi F, Zhang Q, Liu L, Chang X, Xu H. 2023. Novel insights into the role of mitochondria in diabetic cardiomyopathy: molecular mechanisms and potential treatments. Cell Stress and Chaperones 28:641−55

doi: 10.1007/s12192-023-01361-w
[53]

Chen Y, Zhang J, Li P, Liu C, Li L. 2021. N1-methylnicotinamide ameliorates insulin resistance in skeletal muscle of type 2 diabetic mice by activating the SIRT1/PGC-1α signaling pathway. Molecular Medicine Reports 23:270

doi: 10.3892/mmr.2021.11909
[54]

Shen J, Liang W, Zhao R, Chen Y, Liu Y, et al. 2025. Cross-tissue multi-omics analyses reveal the gut microbiota's absence impacts organ morphology, immune homeostasis, bile acid and lipid metabolism. iMeta 4:e272

doi: 10.1002/imt2.272
[55]

Xourafa G, Korbmacher M, Roden M. 2024. Inter-organ crosstalk during development and progression of type 2 diabetes mellitus. Nature Reviews Endocrinology 20:27−49

doi: 10.1038/s41574-023-00898-1
[56]

Martini T, Naef F, Tchorz JS. 2023. Spatiotemporal metabolic liver zonation and consequences on pathophysiology. Annual Review of Pathology 18:439−66

doi: 10.1146/annurev-pathmechdis-031521-024831
[57]

Tilg H, Adolph TE, Trauner M. 2022. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metabolism 34:1700−18

doi: 10.1016/j.cmet.2022.09.017
[58]

Fortelny N, Farlik M, Fife V, Gorki AD, Lassnig C, et al. 2024. JAK-STAT signaling maintains homeostasis in T cells and macrophages. Nature Immunology 25:847−59

doi: 10.1038/s41590-024-01804-1
[59]

Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, et al. 2022. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences 43:136−50

doi: 10.1016/j.tips.2021.11.004
[60]

Jia ZC, Yang X, Wu YK, Li M, Das D, et al. 2024. The art of finding the right drug target: emerging methods and strategies. Pharmacological Reviews 76:896−914

doi: 10.1124/pharmrev.123.001028
[61]

Oostindie SC, Rinaldi DA, Zom GG, Wester MJ, Paulet D, et al. 2022. Logic-gated antibody pairs that selectively act on cells co-expressing two antigens. Nature Biotechnology 40:1509−19

doi: 10.1038/s41587-022-01384-1
[62]

Lameris R, Shahine A, Pellicci DG, Uldrich AP, Gras S, et al. 2020. A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response. Nature Cancer 1:1054−65

doi: 10.1038/s43018-020-00111-6
[63]

Julg B, Walker-Sperling VEK, Wagh K, Aid M, Stephenson KE, et al. 2024. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial. Nature Medicine 30:3534−43

doi: 10.1038/s41591-024-03247-5
[64]

Menéndez-Arias L, Delgado R. 2022. Update and latest advances in antiretroviral therapy. Trends in Pharmacological Sciences 43:16−29

doi: 10.1016/j.tips.2021.10.004
[65]

Yaghmaei E, Lu H, Ehwerhemuepha L, Zheng J, Danioko S, et al. 2024. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients. Communications Medicine 4:99

doi: 10.1038/s43856-024-00527-6
[66]

Lindemann PC, Mylvaganam H, Oppegaard O, Anthonisen IL, Zecic N, et al. 2022. Case Report: whole-genome sequencing of serially collected Haemophilus influenzae from a patient with common variable immunodeficiency reveals within-host evolution of resistance to trimethoprim-sulfamethoxazole and azithromycin after prolonged treatment with these antibiotics. Frontiers in Cellular and Infection Microbiology 12:896823

doi: 10.3389/fcimb.2022.896823
[67]

Mendes C, Valentini G, Chamorro Rengifo AF, Pinto JMO, Silva MAS, et al. 2019. Supersaturating drug delivery system of fixed drug combination: sulfamethoxazole and trimethoprim. Expert Review of Anti-Infective Therapy 17:841−50

doi: 10.1080/14787210.2019.1675508
[68]

Yang M, Jiang XC, Wang L, Cui DA, Zhang JY, et al. 2021. Schisandrin protects against norepinephrine-induced myocardial hypertrophic injury by inhibiting the JAK2/STAT3 signaling pathway. Evidence-Based Complementary and Alternative Medicine 2021:8129512

doi: 10.1155/2021/8129512
[69]

Sun H, Yang L, Li MX, Fang H, Zhang AH, et al. 2018. UPLC-G2Si-HDMS untargeted metabolomics for identification of metabolic targets of Yin-Chen-Hao-Tang used as a therapeutic agent of dampness-heat jaundice syndrome. Journal of Chromatography B 1081−1082:41−50

doi: 10.1016/j.jchromb.2018.02.035
[70]

Fang J, Little PJ, Xu S. 2018. Atheroprotective effects and molecular targets of tanshinones derived from herbal medicine Danshen. Medicinal Research Reviews 38:201−28

doi: 10.1002/med.21438
[71]

Wu R, Zhang L, Xu H, Chen H, Zhao W, et al. 2023. Salvia miltiorrhiza extract prevents the occurrence of early atherosclerosis in ApoE-/- mice via TLR4/ NF-κB pathway. Cardiovascular & Hematological Agents in Medicinal Chemistry 21:232−39

doi: 10.2174/1871525721666230206112134
[72]

Zeng H, Wang L, Zhang J, Pan T, Yu Y, et al. 2021. Activated PKB/GSK-3β synergizes with PKC-δ signaling in attenuating myocardial ischemia/reperfusion injury via potentiation of NRF2 activity: therapeutic efficacy of dihydrotanshinone-I. Acta Pharmaceutica Sinica B 11:71−88

doi: 10.1016/j.apsb.2020.09.006
[73]

Chen Q, Xu Q, Zhu H, Wang J, Sun N, et al. 2023. Salvianolic acid B promotes angiogenesis and inhibits cardiomyocyte apoptosis by regulating autophagy in myocardial ischemia. Chinese Medicine 18:155

doi: 10.1186/s13020-023-00859-w
[74]

Xu X, Mao C, Zhang C, Zhang M, Gong J, et al. 2023. Salvianolic acid B inhibits ferroptosis and apoptosis during myocardial ischemia/reperfusion injury via decreasing the ubiquitin-proteasome degradation of GPX4 and the ROS-JNK/MAPK pathways. Molecules 28:4117

doi: 10.3390/molecules28104117
[75]

Jiang Y, Cai Y, Han R, Xu Y, Xia Z, et al. 2023. Salvianolic acids and its potential for cardio-protection against myocardial ischemic reperfusion injury in diabetes. Frontiers in Endocrinology 14:1322474

doi: 10.3389/fendo.2023.1322474
[76]

Coca A, Kreutz R, Manolis AJ, Mancia G. 2020. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. Journal of Hypertension 38:1890−98

doi: 10.1097/HJH.0000000000002464
[77]

Khotimchenko M, Brunk NE, Hixon MS, Walden DM, Hou H, et al. 2022. In silico development of combinatorial therapeutic approaches targeting key signaling pathways in metabolic syndrome. Pharmaceutical Research 39:2937−50

doi: 10.1007/s11095-022-03231-z
[78]

Ding K, Liu H, Yang H, Zhu H, Ma J, et al. 2024. A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma. Med 5:1393−1401.e2

doi: 10.1016/j.medj.2024.07.007
[79]

Rai A, Kumar V, Jerath G, Kartha CC, Ramakrishnan V. 2021. Mapping drug-target interactions and synergy in multi-molecular therapeutics for pressure-overload cardiac hypertrophy. NPJ Systems Biology and Applications 7:11

doi: 10.1038/s41540-021-00171-z
[80]

de Sena Murteira Pinheiro P, Franco LS, Montagnoli TL, Fraga CAM. 2024. Molecular hybridization: a powerful tool for multitarget drug discovery. Expert Opinion on Drug Discovery 19:451−70

doi: 10.1080/17460441.2024.2322990
[81]

Woo MS, Mayer C, Binkle-Ladisch L, Sonner JK, Rosenkranz SC, et al. 2024. STING orchestrates the neuronal inflammatory stress response in multiple sclerosis. Cell 187:4043−4060.e30

doi: 10.1016/j.cell.2024.05.031
[82]

Li W, Wang X, Wan D, Li J, Jin Z. 2024. Editorial: targeting key cellular signaling network for cancer chemotherapy and immunotherapy. Frontiers in Immunology 15:1423917

doi: 10.3389/fimmu.2024.1423917
[83]

Zhou L, Sun J, Gu L, Wang S, Yang T, et al. 2021. Programmed cell death: complex regulatory networks in cardiovascular disease. Frontiers in Cell and Developmental Biology 9:794879

doi: 10.3389/fcell.2021.794879
[84]

de Goede KE, Driessen AJM, Van den Bossche J. 2020. Metabolic cancer-macrophage crosstalk in the tumor microenvironment. Biology 9:380

doi: 10.3390/biology9110380
[85]

Tian Y, Wan N, Zhang H, Shao C, Ding M, et al. 2023. Chemoproteomic mapping of the glycolytic targetome in cancer cells. Nature Chemical Biology 19:1480−91

doi: 10.1038/s41589-023-01355-w
[86]

Li X, Guo Q, Chen Q, Chu Y, Zhang Y, et al. 2024. Reconciling the cooperative-competitive patterns among tumor and immune cells for triple-negative breast cancer treatment using multimodule nanocomplexes. Advanced Materials 36:e2312219

doi: 10.1002/adma.202312219
[87]

Montinaro A, Areso Zubiaur I, Saggau J, Kretz AL, Ferreira RMM, et al. 2022. Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death & Differentiation 29:492−503

doi: 10.1038/s41418-021-00869-x
[88]

Panneerpandian P, Ganesan K. 2021. Development of a cell-based pathway modulator screening system to screen the targeted cancer therapeutic candidates. Human Cell 34:445−56

doi: 10.1007/s13577-020-00476-x
[89]

Ma Y, Newton PK. 2021. Role of synergy and antagonism in designing multidrug adaptive chemotherapy schedules. Physical Review E 103:032408

doi: 10.1103/PhysRevE.103.032408
[90]

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, et al. 2019. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 20:701−10

doi: 10.1016/S1470-2045(18)30940-9
[91]

Chen Y, Zhou Q, Wang J, Xu Y, Wang Y, et al. 2023. Ligand recognition mechanism of the human relaxin family peptide receptor 4 (RXFP4). Nature Communications 14:492

doi: 10.1038/s41467-023-36182-z
[92]

Gisemba SA, Ferracane MJ, Murray TF, Aldrich JV. 2021. Conformational constraint between aromatic residue side chains in the "message" sequence of the peptide arodyn using ring closing metathesis results in a potent and selective kappa opioid receptor antagonist. Journal of Medicinal Chemistry 64:3153−64

doi: 10.1021/acs.jmedchem.0c01984
[93]

Wang M, Hsieh CY, Wang J, Wang D, Weng G, et al. 2022. RELATION: a deep generative model for structure-based de novo drug design. Journal of Medicinal Chemistry 65:9478−92

doi: 10.1021/acs.jmedchem.2c00732
[94]

Chen L, Fan Z, Chang J, Yang R, Hou H, et al. 2023. Sequence-based drug design as a concept in computational drug design. Nature Communications 14:4217

doi: 10.1038/s41467-023-39856-w
[95]

Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, et al. 2025. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637:940−46

doi: 10.1038/s41586-024-08261-8
[96]

Zhao X, Yu L, Chen Y, Wang Y, Wan H, et al. 2019. Comparative pharmacokinetics of hydrophilic components in Salvia miltiorrhiza Bge. and Carthamus tinctorius L. in rats that underwent cerebral ischemia reperfusion using an HPLC-DAD method. Frontiers in Pharmacology 10:1598

doi: 10.3389/fphar.2019.01598
[97]

Lei W, Li X, Li L, Huang M, Cao Y, et al. 2021. Compound Danshen Dripping Pill ameliorates post ischemic myocardial inflammation through synergistically regulating MAPK, PI3K/AKT and PPAR signaling pathways. Journal of Ethnopharmacology 281:114438

doi: 10.1016/j.jep.2021.114438
[98]

Liu P, Yang H, Long F, Hao HP, Xu X, et al. 2014. Bioactive equivalence of combinatorial components identified in screening of an herbal medicine. Pharmaceutical Research 31:1788−800

doi: 10.1007/s11095-013-1283-1
[99]

Zhao M, Zhou L, Zhang Q, Wang M, Dong Y, et al. 2025. Targeting MAPK14 by lobeline upregulates Slurp1-mediated inhibition of alternative activation of TAM and retards colorectal cancer growth. Advanced Science 12:e2407900

doi: 10.1002/advs.202407900
[100]

Rose JP, Morgan DA, Sullivan AI, Fu X, Inigo-Vollmer M, et al. 2025. FGF21 reverses MASH through coordinated actions on the CNS and liver. Cell Metabolism 37:1515−1529.e6

doi: 10.1016/j.cmet.2025.04.014
[101]

Zheng X, Chen T, Jiang R, Zhao A, Wu Q, et al. 2021. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metabolism 33:791−803.e7

doi: 10.1016/j.cmet.2020.11.017
[102]

García M, Virgili M, Alonso M, Alegret C, Fernández B, et al. 2020. 4-Aryl-1-oxa-4, 9-diazaspiro[5.5]undecane derivatives as dual μ-opioid receptor agonists and σ(1) receptor antagonists for the treatment of pain. Journal of Medicinal Chemistry 63:2434−54

doi: 10.1021/acs.jmedchem.9b01256
[103]

Chen Z, Yu J, Wang H, Xu P, Fan L, et al. 2024. Flexible scaffold-based cheminformatics approach for polypharmacological drug design. Cell 187:2194−2208.e22

doi: 10.1016/j.cell.2024.02.034
[104]

Zhou J, Cui S, He Q, Guo Y, Pan X, et al. 2020. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nature Communications 11:240

doi: 10.1038/s41467-019-14138-6
[105]

Han J, Hu S, Hu Y, Xu Y, Hou Y, et al. 2023. Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. Cancer Immunology Research 11:583−99

doi: 10.1158/2326-6066.CIR-22-0483
[106]

Ma ZZ, Guzikowski NJ, Kim JW, Kavalali ET, Monteggia LM. 2025. Enhanced ERK activity extends ketamine's antidepressant effects by augmenting synaptic plasticity. Science 388:646−55

doi: 10.1126/science.abb6748
[107]

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, et al. 2019. Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery 18:41−58

doi: 10.1038/nrd.2018.168
[108]

Park JW, Chung H, Kim JM, Kim NY, Hong SH, et al. 2024. Pharmacokinetics of a fixed-dose combination product of amlodipine, losartan, ezetimibe, and rosuvastatin and its comparison with co-administration of four individual components in healthy participants. Drugs in R&D 24:179−86

doi: 10.1007/s40268-024-00460-y
[109]

Weth FR, Hoggarth GB, Weth AF, Paterson E, White MPJ, et al. 2024. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British Journal of Cancer 130:703−15

doi: 10.1038/s41416-023-02502-9
[110]

Patrono C. 2024. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. European Heart Journal 45:2362−76

doi: 10.1093/eurheartj/ehae324
[111]

Li Y, Pereda Serras C, Blumenfeld J, Xie M, Hao Y, et al. 2025. Cell-type-directed network-correcting combination therapy for Alzheimer's disease. Cell 188:5516−5534.e18

doi: 10.1016/j.cell.2025.06.035
[112]

Yang J, Xu Z, Wu WKK, Chu Q, Zhang Q. 2021. GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction. Journal of the American Medical Informatics Association 28:2336−45

doi: 10.1093/jamia/ocab162
[113]

Song M, Finley SD. 2020. ERK and Akt exhibit distinct signaling responses following stimulation by pro-angiogenic factors. Cell Communication and Signaling 18:114

doi: 10.1186/s12964-020-00595-w
[114]

Theodoris CV, Xiao L, Chopra A, Chaffin MD, Al Sayed ZR, et al. 2023. Transfer learning enables predictions in network biology. Nature 618:616−24

doi: 10.1038/s41586-023-06139-9
[115]

Krishnan A, Anahtar MN, Valeri JA, Jin W, Donghia NM, et al. 2025. A generative deep learning approach to de novo antibiotic design. Cell 188:5962−5979.e22

doi: 10.1016/j.cell.2025.07.033
[116]

Zhou F, Guo H, Xia Y, Le X, Tan DSW, et al. 2025. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nature Reviews Clinical Oncology 22:95−116

doi: 10.1038/s41571-024-00971-2
[117]

Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, et al. 2022. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nature Reviews Drug Discovery 21:899−914

doi: 10.1038/s41573-022-00472-w
[118]

Martínez-Fructuoso L, Ryan Arends SJ, Freire VF, Evans JR, DeVries S, et al. 2023. Screen for new antimicrobial natural products from the NCI program for natural product discovery prefractionated extract library. ACS Infectious Diseases 9:1245−56

doi: 10.1021/acsinfecdis.3c00067
[119]

Tufail M, Wan WD, Jiang C, Li N. 2024. Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer. Chemico-Biological Interactions 396:111055

doi: 10.1016/j.cbi.2024.111055
[120]

Quesada-Vázquez S, Antolín A, Colom-Pellicer M, Aragonès G, Herrero L, et al. 2022. Reduction of obesity and insulin resistance through dual targeting of VAT and BAT by a novel combination of metabolic cofactors. International Journal of Molecular Sciences 23:14923

doi: 10.3390/ijms232314923
[121]

Wang K, Zhang Z, Hang J, Liu J, Guo F, et al. 2023. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science 381:eadd5787

doi: 10.1126/science.add5787
[122]

Hughes RL, Alvarado DA, Swanson KS, Holscher HD. 2022. The prebiotic potential of inulin-type fructans: a systematic review. Advances in Nutrition 13:492−529

doi: 10.1093/advances/nmab119
[123]

Mahajan P, Gor HR, Jadhav S, Joshi M, Nema V. 2025. Host-directed therapeutic for the treatment of Mycobacterium tuberculosis. Microbiological Research 299:128253

doi: 10.1016/j.micres.2025.128253
[124]

Wang X, Fang Y, Liang W, Wong CC, Qin H, et al. 2024. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell 42:1729−1746.e8

doi: 10.1016/j.ccell.2024.08.019
[125]

Mayer BJ. 1998. Protein–protein interactions in signaling cascades. In Transmembrane Signaling Protocols. Methods in Molecular Biology, ed. Bar-Sagi D, Volume 84. USA: Humana Press. doi: 10.1385/0-89603-488-7:33
[126]

Comba A, Faisal SM, Varela ML, Hollon T, Al-Holou WN, et al. 2021. Uncovering spatiotemporal heterogeneity of high-grade gliomas: from disease biology to therapeutic implications. Frontiers in Oncology 11:703764

doi: 10.3389/fonc.2021.703764
[127]

Vogel A, Martin K, Soukup K, Halfmann A, Kerndl M, et al. 2022. JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction. Cell Reports 38:110420

doi: 10.1016/j.celrep.2022.110420
[128]

Chovatiya R, Paller AS. 2021. JAK inhibitors in the treatment of atopic dermatitis. Journal of Allergy and Clinical Immunology 148:927−40

doi: 10.1016/j.jaci.2021.08.009
[129]

Tamari M, Del Bel KL, Ver Heul AM, Zamidar L, Orimo K, et al. 2024. Sensory neurons promote immune homeostasis in the lung. Cell 187:44−61.e17

doi: 10.1016/j.cell.2023.11.027
[130]

Li A, Chen HJ, Yang JJ. 2023. Design and rationale for a phase II, randomized, open-label, two-cohort multicenter interventional study of osimertinib with or without savolitinib in de novo MET aberrant, EGFR-mutant patients with advanced non-small-cell lung cancer: the FLOWERS trial. Clinical Lung Cancer 24:82−88

doi: 10.1016/j.cllc.2022.09.009
[131]

Chelliah V, van der Graaf PH. 2022. Model-informed target identification and validation through combining quantitative systems pharmacology with network-based analysis. CPT: Pharmacometrics & Systems Pharmacology 11:399−402

doi: 10.1002/psp4.12766
[132]

Kong HJ, Mooney DJ. 2007. Microenvironmental regulation of biomacromolecular therapies. Nature Reviews Drug Discovery 6:455−63

doi: 10.1038/nrd2309
[133]

Dumican M, Reyers T, Malczewski A, Thijs Z. 2025. The effect of genotype on self-reported dysarthria and dysphagia in Parkinson's disease: a Parkinson's progression marker initiative study. International Journal of Language & Communication Disorders 60:e70124

doi: 10.1111/1460-6984.70124
[134]

van der Lee M, Swen JJ. 2023. Artificial intelligence in pharmacology research and practice. Clinical and Translational Science 16:31−36

doi: 10.1111/cts.13431
[135]

Ali Z, Zibert JR, Thomsen SF. 2020. Virtual clinical trials: perspectives in dermatology. Dermatology 236:375−82

doi: 10.1159/000506418
[136]

Li T, Yang Y, Qi H, Cui W, Zhang L, et al. 2023. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy 8:36

doi: 10.1038/s41392-023-01309-7
[137]

Harrer DC, Dörrie J, Schaft N. 2023. CARs and drugs: pharmacological ways of boosting CAR-T-cell therapy. International Journal of Molecular Sciences 24:2342

doi: 10.3390/ijms24032342
[138]

Cicchese JM, Sambarey A, Kirschner D, Linderman JJ, Chandrasekaran S. 2021. A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs. Scientific Reports 11:5643

doi: 10.1038/s41598-021-84827-0
[139]

Huang J, Fu Y, Wang A, Shi K, Peng Y, et al. 2024. Brain delivery of protein therapeutics by cell matrix-inspired biomimetic nanocarrier. Advanced Materials 36:e2405323

doi: 10.1002/adma.202405323